Day One Biopharmaceuticals Is A Commercial Stage Biopharmaceutical Company Focused On Developing Innovative Medicines For Childhood And Adult Cancersthe Teamcomposed Of Oncologistsscientistsand Business Leadersaims To Expedite The Delivery Of Targeted Therapies To Patients In Needby Leveraging Insights From Childhood Cancer Biologyday One Seeks To Create Treatments That Benefit Patients Of All Ages The Company Is Advancing Cancer Research Through Collaborations With Pediatric Oncology Investigatorswhich Helps Identify And Develop Promising Therapiesday One S Product Pipeline Includes Ojemdatovorafenib A Raf Inhibitor Approved For Treating Relapsed Or Refractory Pediatric Low Grade Gliomaand Day301An Antibody Drug Conjugate Targeting Ptk7 Currently In Preclinical Developmentadditionallyday One Has A Partnership With Ipsen To Commercialize Tovorafenib Outside The U S Enhancing Its Ability To Impact Patient Care
